<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366698">
  <stage>Registered</stage>
  <submitdate>16/07/2014</submitdate>
  <approvaldate>31/07/2014</approvaldate>
  <actrnumber>ACTRN12614000815662</actrnumber>
  <trial_identification>
    <studytitle>A prospective randomised double-blind, double-dummy, placebo-controlled crossover study to determine whether Glucagon-like peptide-1 (GLP-1) stimulates or suppresses pancreatic exocrine function in health.</studytitle>
    <scientifictitle>A prospective randomised double-blind, double-dummy, placebo-controlled crossover study on 15 healthy male participants to determine whether Glucagon-like peptide-1 (GLP-1) stimulates or suppresses pancreatic exocrine function in health.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperglycaemia</healthcondition>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Critical Illness-induced hyperglycaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IV GLP-1 (1.2 pmol/kg/min) infusion or placebo will be administrated to participants over 2 visits. Participants will receive a second IV containing either Secretin (75ng/kg/hr) and CCK (20ng/kg/hr) or placebo over 2 visits. Adherence of intervention will be monitored by both the clinical trial pharmacy and the researchers in the study to ensure the participants receive the correct treatment/placebo on any given trial day. Participants will be studied over 4 occasions, separated by at least 4 days.</interventions>
    <comparator>On visits when participants aren't receiving GLP-1 or Secretin + CCK they will receive human albumin and saline, respectively.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether GLP-1 acutely stimulates pancreatic exocrine function in health. This will be assessed by peak duodenal bicarbonate concentration and pancreatic bicarbonate output.

Peak duodenal amylase concentrations and amylase concentration area under the curve.</outcome>
      <timepoint>Duodenal Aspirates will be collected every 15 mins for an hour to assess pancreatic function</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in plasma amylase and lipase</outcome>
      <timepoint>Bloods will be taken every 15 mins for an hour.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Male volunteers between the ages of 18-35
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Inability to give informed consent
History of diabetes
History of pancreatitis
Lipase level &gt;210 U/L
Amylase level &gt; 110 U/L
Estimated glomerular filtration rate &lt; 60ml/min
Impared liver function (ALT &gt;55 U/L; Albumin &lt;34g/l, ALP &gt;110 U/L; Bilirubin &gt;25 umol; GGT &gt; 80 U/L)
Haemoglobin &lt;135g/L
HbA1c &gt;6%
Body Mass Index &gt;32kg/m2
Smoking &gt; 10 cigarettes/day
Alcohol consumption &gt;20g/day
Volunteers who have donated blood in the preceding 3 months
Female volunteers of child bearing age
Suffer from any chronic medical conditions such as (but not limited to) heart failure, ischaemic heart disease, chronic lung disease, autonomic dysfunction resulting from any cause active or previously treated malignancy, chronic infections (e.g viral hepatitis and HIV)
Suffered from any acute medical illnesses during the 4 week period before recruitment
Contraindications to any of the drugs used in this study (e.g. known hypersensitivity)
Gallstone(s) visualised on ultrasound at the screening visit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be enrolled using an enrollment number and data will be sent to the Royal Adelaide Hospital clinical trials pharmacy department to be randomised for drug treatments. </concealment>
    <sequence>Randomisation will be completed by the clinical trials pharmacy department using a randomisation table created by computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Sample size was generated from previous studies assessing secretin stimulation on chronic pancreatitis. However, due to the novelty of the study there are no directly related studies.

Outcome variables will be analysed using an appropriate statistical methods.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>10/02/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Adam Deane</primarysponsorname>
    <primarysponsoraddress>ICU Research 
Royal Adelaide Hospital
North Terrace
Adelaide 
SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council Grant</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601

Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>OUTCOMES

The primary outcome measures are
*peak duodenal bicarbonate concentration and pancreatic bicarbonate output (bicarbonate volume times bicarbonate concentration)
*peak duodenal amylase concentration and amylase concentration area under the curve (time equals 0 to 60 minutes)

Secondary outcome measures are
*Plasma concentrations of amylase and lipase 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Ethics Committee</ethicname>
      <ethicaddress>North Terrace 
Adelaide
SA 5000
</ethicaddress>
      <ethicapprovaldate>11/07/2014</ethicapprovaldate>
      <hrec>140604</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Marianne Chapman</name>
      <address>Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 4624</phone>
      <fax />
      <email>Marianne.Chapman@sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Marianne Chapman</name>
      <address>Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 4624</phone>
      <fax />
      <email>Marianne.Chapman@sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Marianne Chapman</name>
      <address>Royal Adelaide Hospital
North Tce
Adelaide  5000
South Australia</address>
      <phone>+6188222 4624</phone>
      <fax />
      <email>Marianne.Chapman@sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>